The pharmaceutical industry is one of the most dynamic and powerful sectors in Bangladesh.  It is technologically one of the most developed manufacturing industries and currently contributes about one percent to total GDP with great potential for expansion.  Total domestic healthcare expenditures are currently approximately three percent of GDP, offering substantial opportunity for domestic pharmaceutical sales in addition to exports.  The World Trade Organization's (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPs) agreement permits Bangladesh to reverse-engineer patented generic pharmaceutical products to sell locally and export to markets around the world.

1. WEL COME TO
OUR
PRESENTATION

2. Export Potentiality of Pharmaceutical goods in
Bangladesh

3. NAME ID
Nowsin Musarrat BBA01150105499
Meghla Bhowmick BBA01150105521
MD.Hafizur Rahman BBA140205447
MD.A.kader BBA0150305634
Arif Hossain BBA01150105529

4. Introduction:
The pharmaceutical industry is one of the most dynamic and
powerful sectors in Bangladesh. It is technologically one of the
most developed manufacturing industries and currently contributes
about one percent to total GDP with great potential for
expansion. Total domestic healthcare expenditures are currently
approximately three percent of GDP, offering substantial opportunity
for domestic pharmaceutical sales in addition to exports. The World
Trade Organization's (WTO) Trade-Related Aspects of Intellectual
Property Rights (TRIPs) agreement permits Bangladesh to reverse-
engineer patented generic pharmaceutical products to sell locally and
export to markets around the world.

5. Bangladesh’s Growing Pharmaceutical Sector
• The export value of pharmaceuticals is growing at a reasonable rate
every year. Exports increased from $8.2 million in 2004 to $43.63
million in 2013.Export destinations are also increasing in number.
• Bangladesh’s strict quality compliance gives pharmaceuticals an
advantage to compete with producers in India, China, Brazil and
Turkey in the overseas export markets. The capability of the
industry has helped it achieve excellence as per the general
international standards.

6. Export of Pharmaceutical goods
• To export products to developed markets, companies
must bring their factories in accordance with Good
Manufacturing Process (GMP) standards.
• Bangladesh is not only exporting pharmaceuticals
products to Bhutan, Nepal, Sri Lanka, Pakistan, but also
to Thailand, Singapore, Myanmar, Vietnam Yemen,
Oman, and some countries of Central Asia and Africa. It
has even captured a larger market in Europe.

7. Some experts attribute the spectacular growth to favorable
government policy and a special focus on producing quality products.
In particular, two issues have been a driving force for pharmaceutical
export market in Bangladesh. They include:
• a relaxation on intellectual property rights granted by the WTO for
the least developed countries until 2033
• 2 Bangladeshi companies – Square Pharmaceuticals and Beximco
Pharma – obtaining FDA accreditation in June 2015. Other
companies are expected to follow suit.

8. Share of market revenue
There are currently around 100 Bangladeshi pharmaceutical
companies in operation. The industry is highly concentrated
as the top 20 companies generate 85 percent of the
revenue. The top ten manufacturers by share of market
revenue are as follows: Square (19 percent),Incepta(9.5
percent),Beximco(9 percent),Opsonin(5 percent),Renata (4.9
percent), Eskayef (4.7 percent), ACI (4.3 percent), ACME
(4.1 percent),Aritstopharma (4 percent), and Drug
International (3.7 percent). Local manufacturers dominate
the industry, enjoying about 90 percent market share while
multinationals hold 10 percent

9. 2014 2015 2016
2017
(Estimated)
Market Size $1,338,380 $1,505,860 $1,686,563 $1,897,000
Local
Production
(97% of market,
estimated)
$1,298,228 $1,460,684 $1,635,966 $1,843,500
Imports N/A N/A N/A N/A
Exports $9,398 $11,278 $14,097 $17,540
Total Market
Size
N/A N/A N/A N/A

10. Support needs to buster export:
Removal of export barriers.
Strengthening of drug administration.
Development of independent drug testing laboratory DTL.
Development of clinical testing / Bioequivalence centers.
Establish API Industry Park.
Introduce CGMP (Current Good Manufacturing Practice) training.
Dedicated pharma zone ( Temperature control area) at sea / Airports
Suggested changes in patent law to make use of TRIPS Agreement

11. Opportunities:
Multinational and large national companies generally follow current
good manufacturing practices (cGMP) including rigorous quality
control of their products. The pharmaceutical market trend is shifting
toward unconventional drugs where there is greater opportunity for
foreign investment. The areas of primary demand are
Veterinary and human vaccines;
Drug development and contract research outsourcing from European
countries, including the United Kingdom. Examples include
ophthalmic pharmaceuticals and cardio-vascular medication;
Clinical trials of new pharmaceuticals;
Biological drugs (for instance, insulin and hepatitis);
Disease modifying drugs (for instance, anti-cancer medications);
Hormonal therapies.

12. SL
Company Name Country Name Export Amount
1 ACI Limited Swaziland 1,500,000.00
2 ACI Limited United States 17,800,000.00
3 Acme Laboratories Ltd. American Samoa 150,000.00
4 Acme Laboratories Ltd. Canada 1,245,800.00
5 Acme Laboratories Ltd. United Kingdom 1,402,210.00
6 Alpha Pharmaceuticals Australia 18,950,000.00
7 Novartis (Bangladesh) Ltd. China 20,000,000.00
A country wise export data for 2014-2015 is given below:

13. Foreign Competition:
At the very beginning, foreign firms were dominating in our domestic
market. Until now, the domestic pharmaceuticals industries are facing
foreign competition. However, the domestic firms are not afraid of the
foreign competitors; it is also competing against them.

14. Last 3 Years Total Exporting Data
YEAR Amount (Million US$)
2014-2015 43.63
2012-2013 48.25
2010-2011 44.27
From the above table, it can be concluded that the trend of export is
moving upward. However, there is a huge fall in 2014-2015; Drug
Administration still hopes that the positive trend will continue in
future.

15. Challenges & problems faced while exporting:
• No sufficient incentives for the growth of the industry
• Lack of proper governmental legislation and the implementation
of the laws by the drug administration
• Unstable political situation and different types of violence within
the nation, so not achieving the expectation in export
• An effect of globalization that has increased the competition
• Foreign competitors have more equipment, technology, and plant
facilities than that of domestic firms

16. Opportunities of Exporting Pharmaceutical Goods:
Still there are opportunities for the industry to do well in the future
• Foreign competitions made the country firms more suitable to face
challenges that arose after the year 2005
• Increased competition, so improved quality of medicinal products
• competitive environment is necessary, for surviving in the future
• Monopoly can be reduced from the international market
• Increase foreign currency reserve
• Improve trade account, and balance of payment
• More customers as well as market share can be gained

17. Barriers:
 High cost of registration for their export items and restriction on
transfer of funds forpromotional activities.
 The fixed mark-up system of pricing helped keep the prices of
pharmaceutical products low; this made it difficult to cover costs of
marketing and distribution.
 In order to export a drug to a regulated market and to some
moderately regulated market, itis mandatory to provide
bioequivalence data. At present there is no exist in Bangladesh and
we have to conduct this experiment abroad at a highprice.4.

18. Conclusion
Amongst the LDC’s countries Bangladesh is doing much better
business in pharmaceuticals
sector. Every year its total export amount is increasing marginally. So
far we seen that its export value has reached $41million but compare to
India we are way behind them. According to BMIs Pharmaceutical &
Healthcare Business Environment Ratings our position is 40 out 100
and still
we couldn’t reach the regional avg. which is 53.1. Most importantly
our exempt
ion period of patent protection is until 2016 which is close to
expiration.